Compare Salesforce Inc (CRM) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Salesforce Inc vs Moderna, Inc. — how do they compare? Salesforce Inc trades at $229.13 (market cap $187.48B), while Moderna, Inc. trades at $225 (market cap $78.65B). The key difference: Salesforce Inc is far larger — about 2.4× Moderna, Inc.'s market cap, and Salesforce Inc pays a 0.77% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Salesforce Inc for 89 Days and Moderna, Inc. for 59 Days on average.
| CRM | MRNA | |
|---|---|---|
Market Cap | $187.48B | $78.65B |
Volume | 6,155,822 | 37,373,437 |
Sector | Technology | Health |
52-Week High | $266.23 | $203.46 |
52-Week Low | $150.12 | $22.36 |
Typical Hold Time | 89 Days | 59 Days |
Enterprise Value | $217.82B | $74.80B |
Dividend Yield | 0.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Salesforce (CRM) trades at $227.80, up 1.44% today, but remains under technical pressure with a bearish signal. The company demonstrates strong fundamentals with consistent earnings beats, 77.28% gross margins, and 21.99% net income margins. Recent AI-driven growth initiatives show promise, with Agentforce and Data 360 ARR reaching $2.9 billion. However, the stock faces headwinds from broader software sector weakness and AI disruption concerns.
The investment case balances strong profitability and AI monetization potential against sector-wide pressures. With 76.5% analyst buy ratings and a $271.91 consensus target offering 19% upside, the stock appears fundamentally undervalued. Key risks include AI competition, macroeconomic sensitivity, and the recent 35% YTD decline testing investor patience despite solid financial performance.
Moderna (MRNA) trades at $197.00, up 0.26% on the day, with technical indicators showing a bullish trend and strong momentum. The stock has rallied over 500% in 2026, driven by positive clinical updates for its cancer vaccine pipeline and inclusion in the Nasdaq-100 index effective October 9, 2026. However, fundamentals remain challenging with revenue declining from $18.9B in 2022 to $1.9B in 2025 and negative net income margins exceeding 140%.
While technical momentum and pipeline optimism support near-term upside, valuation appears stretched with P/S of 35.08 and negative profitability metrics. Key risks include execution on non-COVID products, competitive pressure, and sustainability of recent gains. Analyst consensus is cautious with only 28% buy ratings and $115.70 price target suggesting significant downside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Salesforce Inc
Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
Read more on CRM →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
